Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q86XK2

UPID:
FBX11_HUMAN

ALTERNATIVE NAMES:
Protein arginine N-methyltransferase 9; Vitiligo-associated protein 1

ALTERNATIVE UPACC:
Q86XK2; A1L491; Q52ZP1; Q53EP7; Q53RT5; Q8IXG3; Q96E90; Q9H6V8; Q9H9L1; Q9NR14; Q9UFK1; Q9UHI1; Q9UKC2

BACKGROUND:
The F-box only protein 11, recognized alternatively as Protein arginine N-methyltransferase 9 and Vitiligo-associated protein 1, is integral to the SCF E3 ubiquitin-protein ligase complex. It mediates the ubiquitination and subsequent degradation of several key proteins, influencing germinal center B-cells differentiation, TGF-beta signaling, and cell-cycle regulation. Additionally, it modulates the activity of phosphorylated p53/TP53, playing a role in transcriptional regulation.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities, F-box only protein 11 emerges as a promising target for therapeutic intervention. Exploring its mechanisms further could lead to groundbreaking treatments for this and potentially other genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.